ASH 2025 | Primary efficacy analysis of TKI and inotuzumab ozogamicin-based therapy for newly diagnosed Ph+ ALL
Anand Patel, MD, University of Chicago Medical Center, Chicago, IL, discusses the primary efficacy analysis of a Phase II study (NCT04747912) investigating tyrosine kinase inhibitor (TKI) and inotuzumab ozogamicin-based therapy for newly diagnosed Philadelphia-chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). He highlights the high rates of major molecular response and measurable residual disease (MRD) negativity achieved with this combination, and notes that the study demonstrated the feasibility of enhancing molecular response by switching from dasatinib to ponatinib. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
